Nektar Therapeutics Stock Analysis, Valuation (NASDAQ:NKTR)

Add to My Stocks
$21.39 $0.36 (1.66%) NKTR stock closing price Sep 20, 2017 (Closing)
Watch Robo Advisor Video of NKTR Stock Analysis
Nektar Therapeutics
Updated on : Sep 20, 2017
previous close
NKTR 21.4 (0%)
S&P 500 2508.2 (0%)
Closing Price On: Sep 20, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
9.5%
Operating Profit
Operating Margin:
-127.8%
Sector Average:
-2.3%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
248.1M
Debt/Equity Ratio:
 73.4
Compared to the industry
Cash Flow
Operating cash flow:
-$58.5M
Net Income:
-$59.9M
PROS      CONS
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
NKTR PS :
25
Industry PS :
5.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-193.5%
Return on Equity:
-3588.9%
Free Cash Flow Margin:
-175.7%
Double Tap To Exit Full Screen
0:00
/

Nektar Therapeutics Stock Analysis

90 5 2

View Nektar Therapeutics stock analysis video. This is our analyst opinion covering the buy and sell arguments for NKTR stock.

Nektar Therapeutics Stock Rating 2.3/5

Our Nektar Therapeutics stock opinion is based on fundamentals of the company. This Nektar Therapeutics stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy NKTR stock?

  • The company saw a significant growth in revenue with a 5 year CAGR of 9.5%.

Should you sell NKTR stock?

  • Nektar Therapeutics registered a negative operating margin of -127.8% (average) over the Trailing Twelve Months (TTM).
  • Nektar Therapeutics registered an average TTM Net loss of -157.1%.
  • With a debt/equity ratio of  73.4, Nektar Therapeutics is highly leveraged in comparison to Medical peers.
  • The lack of profits renders the PE ratio useless for NKTR stock.
  • The company is trading at a price to sales multiple of 25, which is higher in comparison to the Medical-Drugs industry average of 5.4, making NKTR stock expensive.
  • Nektar Therapeutics has a negative ROIC (Return on Invested Capital) of -193.5%.
  • Nektar Therapeutics has a negative ROE (Return On Equity) of -3588.9%, indicating the company is not profitable.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -175.7%.

Comments on this video and Nektar Therapeutics stock